土耳其骨质疏松症负担：记分卡和经济模型。

The burden of osteoporosis in Turkey: a scorecard and economic model.

机构信息

Amgen Inc., 6775 Financial Dr #100, Mississauga, ON, L5N 0A4, Canada.

Amgen Inc., Thousand Oaks, CA, USA.

出版信息

Arch Osteoporos. 2020 Aug 13;15(1):128. doi: 10.1007/s11657-020-00801-9.

DOI:10.1007/s11657-020-00801-9

PMID:32794017

Abstract

UNLABELLED

The burden of osteoporosis in Turkey is not well characterized. Our results indicate that osteoporosis is undertreated in Turkey with 1.35 million fractures predicted to occur from 2019 to 2023 at an associated cost of 2.42 billion USD. Interventions are needed to close the treatment gap and minimize the economic burden.

PURPOSE

The number of osteoporotic fractures is expected to increase as populations age, posing a major risk to health systems and patients. We created a scorecard summarizing the burden of disease, policy framework, service provision, and service uptake for osteoporosis in Turkey and estimated the economic burden of osteoporotic fractures in Turkey.

METHODS

A systematic review of osteoporosis in Turkey was performed. Gaps in the literature were supplemented by surveys with osteoporosis experts. The findings were used to populate a scorecard and burden of illness model focused on adults aged 50 to 89 years in Turkey. The scorecard provided a visual representation of osteoporosis burden and management using a traffic light color coding system. The model quantified osteoporosis-related fracture costs (2019 USD) including hospitalizations, dual-energy x-ray absorptiometry testing, hip fracture surgery, prescription drugs, and patient productivity losses.

RESULTS

The scorecard showed that osteoporosis is undertreated in Turkey. Despite timely access to diagnosis, > 75% of high-risk patients fail to initiate on appropriate therapies. In 2019, the economic model predicted that 255,183 osteoporosis-related fractures would occur in Turkey with an associated annual cost of approximately 455 million USD and an average burden per 1000 at risk of 23,987 USD. The cumulative 5-year cost of 1,354,817 fractures was 2.42 billion USD.

CONCLUSIONS

Approximately 1.35 million fragility fractures are predicted to occur in Turkey during the next 5 years with costs of 2.42 billion USD. Closing the treatment gap will be imperative for preventing these fractures and minimizing the burden of osteoporosis in Turkey.

摘要

背景

土耳其的骨质疏松症负担尚未明确。我们的研究结果表明，土耳其骨质疏松症的治疗不足，预计 2019 年至 2023 年期间将发生 135 万例骨折，相关费用为 24.2 亿美元。需要采取干预措施来缩小治疗差距并最小化经济负担。

目的

随着人口老龄化，骨质疏松性骨折的数量预计将会增加，这对卫生系统和患者构成重大风险。我们创建了一个记分卡，总结了土耳其骨质疏松症的疾病负担、政策框架、服务提供和服务利用率，并估计了土耳其骨质疏松性骨折的经济负担。

方法

对土耳其骨质疏松症进行了系统评价。通过对骨质疏松症专家进行调查，对文献中的空白进行了补充。将研究结果用于填充一个记分卡和疾病负担模型，该模型主要关注土耳其 50 至 89 岁的成年人。记分卡使用交通灯颜色编码系统直观地表示骨质疏松症负担和管理。该模型量化了骨质疏松性骨折相关的成本（2019 年美元），包括住院、双能 X 线吸收法检测、髋部骨折手术、处方药物和患者生产力损失。

结果

记分卡显示，土耳其骨质疏松症的治疗不足。尽管及时获得了诊断，但>75%的高危患者未能开始适当的治疗。2019 年，经济模型预测土耳其将发生 255183 例骨质疏松性骨折，每年相关费用约为 4.55 亿美元，每 1000 名高危患者的平均负担为 23987 美元。1354817 例骨折的 5 年累计成本为 24.2 亿美元。